The diamant alpin dialysis cohort study: Clinico-biological characteristics and cardiovascular genetic risk profile of incident patients

Journal of Nephrology

Volumn 17, Issue 1, 2004, Pages 66-75

  Pernod, Gilles ^a   Bosson, Jean Luc ^a   Golshayan, Dela ^b   Barro, Claire ^a   Alloati, Sandro ^c   Turc Baron, Cécile ^d   Quarello, Francesco ^e   Jeantet, Alberto ^f   Von Albertini, Beat ^g   Forêt, Michel ^h   Laurent, Guy ⁱ   Cordonnier, Daniel ^a   Piccoli, Giuseppe ^f   Wauters, Jean Pierre ^b,j  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Aosta Hospital   (Italy)

^d Centre Hospitalier de la Region d'Annecy   (France)

^e S GIOVANNI BOSCO HOSPITAL   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g Clinic Cecil   (Switzerland)

^h AGDUC   (France)

ⁱ Tassin Center for Dialysis   (France)

^j UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Chronic dialysis; Epidemiology; Genotypic determination; Homocysteinemia; Kidney failure; Progression of kidney disease; Treatment

Indexed keywords

APOLIPOPROTEIN E4; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE; ERYTHROPOIETIN; HAPTOGLOBIN; HEMOGLOBIN; HOMOCYSTEINE; LIPOPROTEIN A; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; ANEMIA; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FRANCE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS; HUMAN; HYPERTENSION; ITALY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POPULATION DISTRIBUTION; POPULATION RESEARCH; PROSPECTIVE STUDY; RISK FACTOR; SWITZERLAND;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GENOTYPE; HAPTOGLOBINS; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RISK FACTORS;

EID: 11144355039     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (suppl 12): S16-23.
2. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2411-7.
3. Ganesh SK, Hulbert-Shearon T, Port F, Eagle K, Stack AG. Mortality differences by dialysis modality among incident patients with and without coronary artery disease. J Am Soc Nephrol 2003; 14: 415-24.
4. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross sectional study. J Am Soc Nephrol 2001; 12: 1516-23.
5. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T. Incidence, outcome, and risk factors of cerebro-vascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 1998; 31: 991-6.
6. O'Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2838-47.
7. Halimi S, Zmirou D, Benhamou PY, Balducci F, Zaoui P, Maghlaoua M, Cordonnier D. Huge progression of diabetes prevalence and incidence among dialysed patients in mainland France and overseas French territories. A second national survey six years apart. (UREMIDIAB 2 study). Diabetes Metab 1999; 25: 507-12.
8. Malatino LS, Benedetto FA, Mallamaci F, Tripepi G, Zoccali C, Parlongo S, Cutrupi S, Marino C, Panuccio V, Garozzo M, Candela V, Bellanuova I, Cataliotti A, Rapisarda F, Fatuzzo P, Bonanno G, Seminara G, Stancanelli B, Tassone F, Labate C. Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular risk extended evaluation in dialysis patients. J Nephrol 1999; 12: 256-60.
9. Qureshi R, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergström B. Inflammation, malnutrition and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 13 (suppl 1): S28-36.
10. Zoccali C. Cardio-vascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-57.
11. Alloatti S, Manes M, Paternoster G, Gaiter AM, Molino A, Rosati C. Peritoneal dialysis compared with hemodialysis in the treatment of end-stage renal disease. J Nephrol 2000; 13: 331-42.
12. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
13. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997; 11: 217-23.
14. Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997; 14: 17-23.
15. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-76.
16. Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R. Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transplant 1997; 12: 691-3.
17. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol 1999; 10: 1027-36.
18. Kimura H, Gejyo F, Suzuki S, Takeda T, Miyazaki R, Yoshida H. A C677T mutation in the methylenetetrahydrofolate reductase gene modifies serum cysteine in dialysis patients. Am J Kidney Dis 2000; 36: 925-33.
19. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
20. Wong TY, Poon P, Szeto CC, Chan JC, Li PK. Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 2000; 57: 632-8.
21. Golshayan D, Paccaud F, Wauters JP. Epidémiologie de l'insuffisance rénale terminale: Comparaison entre deux cantons suisses. Néphrologie 2002; 23: 174-84.
22. Labeeuw M. Traitement de l'insuffisance rénale terminale par dialyse en Rhône-Alpes: évolution sur la période 1993-1999. Néphrologie 2001; 22: 161-6.
23. Van Manen JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT for the NECOSAD-study group. Adjustment for comorbidity in studies on health status in ESRD patients: Which comorbidity index to use? J Am Soc Nephrol 2003; 14: 478-85.
24. Ducros V, Schmitt D, Pernod G, Faure H, Polack B, Favier A. Gas chromatographic-mass spectrometric determination of total homocysteine in human plasma by stable isotope dilution: Method and clinical applications. J Chromatogr B Biomed Sci Appl 1999; 729: 333-9.
25. Sacchi E, Tagliabue L, Duca F, Mannucci PM. High frequency of the C677T mutation in the methylenetetrahydrofolate reductase gene in northern Italy. Thromb Haemost 1997; 78: 963-4.
26. Balasa VV, Gruppo RA, Glueck CJ, Stroop D, Becker A, Pillow A, Wang P. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999; 81: 739-44.
27. Staessen JA, Ginocchio G, Wang JG, Saavedra AP, Soubrier F, Vlietinck R, Fagard R. Genetic variability in the renin-angiotensin system: Prevalence of alleles and genotypes. J Cardiovasc Risk 1997; 4: 401-22.
28. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-600.
29. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV. The Strong Heart Study. Haptoglobin phenotypes is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol 2002; 40: 1984-90.
30. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study. Kidney Int 2003; 63: 1462-7.
31. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2392-7.
32. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
33. Fodinger M, Mannhalter C, Wolfl G, Pabinger I, Muller E, Schmid R, Horl WH, Sunder-Plassmann G. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-23.
34. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60: 1106-13.
35. Stenvinkel P, Heimburger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53: 1336-42.
36. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, Von Eckardstein A. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-15.
37. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-5.
38. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997; 99: 1585-95.
39. Fernandez-Llama P, Poch E, Oriola J, Botey A, Coll E, Darnell A, Rivera F, Revert L. Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephro-angiosclerosis. Kidney Int 1998; 53: 1743-7.
40. Aucella F, Vigilante M, Margaglione M, Grandone E, del Popolo A, Forcella M, Procaccini D, Salatino G, Passione A, Ktena M, De Min A, Stallone C. Polymorphism of the angiotensin-converting enzyme gene in end-stage renal failure patients. Nephron 2000; 85: 54-9.
41. Segarra A, Chacon P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolome J, Camps J, Moliner E, Pelegri A, Marco F, Olmos A, Piera L. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12: 1255-63.